ALISO VIEJO, Calif., May 2, 2019 /PRNewswire-PRWeb/ -- Researchers from Ambry Genetics (Ambry), a leading clinical
Jill S. Dolinsky, director of clinical affairs at Ambry Genetics, explained why this research is significant: "Multigene panel testing (MGPT) is now the preferred method for clinicians testing for HBOC because it enables adherence to the latest NCCN guidelines, which now include medical management recommendations for people with mutations in 16 different genes. Unfortunately, adoption of MGPT has outpaced insurance coverage. We felt there was a need to quantify how current insurance coverage guidelines impact patient access to testing and subsequent clinical management."
Ambry assessed MGPT orders for patients insured by three major insurance carriers. Results revealed significant disparities among insurers as to the number and type of the 16 genes outlined in NCCN management guidelines covered. On a patient level, overlaying these results with NCCN management guidelines indicate that 25.6% of patients who should consider breast MRI screening and 10.5% of patients who should consider risk-reducing surgery for ovarian cancer would be missed if testing was limited to the genes covered under the insurance medical policies.
"On the patient level, the impact of these discrepancies is serious," said Rob Guigley, vice president of market access at Ambry Genetics. "In line with a limited number of the nation's largest insurers, the data highlight the urgent need for payers to update their medical policy to be in step with the NCCN guidelines to ensure at-risk patients have access to HBOC genetic testing and can benefit from early detection and a potential reduction of their cancer risk."
Presentation #581999 is being presented on Friday, May 3rd, 2019, 6:00-7:30 PM at the ASBrS Annual Meeting.
About Ambry Genetics Ambry Genetics is a leader in clinical diagnostic and software solutions, combining both to offer comprehensive and high-quality genetic testing. As part of the Konica Minolta family, Ambry Genetics is responsibly applying new technologies to the molecular diagnostics market to bring about precision medicine. With over 20 years of experience, Ambry Genetics has longstanding expertise in clinical genetic testing. For more information about Ambry Genetics, visit http://www.ambrygen.com.
Press Contact: June Fujimoto press(at)ambrygen.com 949-301-2454
SOURCE Ambry Genetics
Subscribe to our Free Newsletters!